Abraxane Improves Survival in Pancreatic Cancer
Abraxane® (nab-paclitaxel) prolonged life in patients with metastatic pancreatic cancer by an average of two months longer than chemotherapy and significantly increased the percentage of patients who survived for up to two years, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco.
Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging.
Gemzar® (gemcitabine) has been a standard chemotherapy drug for the treatment of advanced pancreatic cancer for some time. Abraxane is a novel form of the widely used cancer drug Taxol (paclitaxel). In Abraxane, the paclitaxel is bound to albumin, a human protein in tiny particles. This formulation improves the delivery of the drug directly to cancer cells and reduces side effects.
The study included 861 patients with metastatic pancreatic cancer who were randomized to receive Abraxane plus Gemzar or Gemzar alone. The primary endpoint of the study was overall survival. The results indicated that patients who received Abraxane and Gemzar had a median overall survival of 8.5 months, compared with 6.7 months for those who received Gemzar alone.
What’s more—Abraxane appeared to improve long-term survival, demonstrating a 59 percent increase in one-year survival, with 35 percent of patients alive at one year compared to 22 percent of those who received Gemzar alone. Abraxane doubled the two-year survival rate—9 percent of patients were still alive at two years, compared with 4 percent of those who had Gemzar alone.
Abraxane also improved median progression-free survival. Patients taking Abraxane/Gemzar survived 5.5 months before their disease progressed, compared to 3.7 months in patients who took Gemzar alone. The overall response rate (patients who experienced tumor shrinkage) was 23 percent for Abraxane/Gemzar compared with 7 percent for Gemzar alone.
Abraxane was well tolerated, though did carry a significantly higher incidence of peripheral neuropathy (numbness in the fingers or toes) than Gemzar—17 percent versus less than 1 percent.
Based on the results of this study, the drug manufacturers plan to seek approval for Abraxane in pancreatic cancer.
Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Journal of Clinical Oncology. 2012; 30(suppl 34): Abstract LBA148.
Copyright © 2013 CancerConsultants. All Rights Reserved.